These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 11986149)

  • 21. Addition of cognitive-behaviour therapy for obsessive-compulsive disorder patients non-responding to fluoxetine.
    Kampman M; Keijsers GP; Hoogduin CA; Verbraak MJ
    Acta Psychiatr Scand; 2002 Oct; 106(4):314-9. PubMed ID: 12225499
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Obsessive-compulsive disorder: evaluation of clinical and biological circadian parameters during fluoxetine treatment.
    Millet B; Touitou Y; Poirier MF; Bourdel MC; Amado I; Hantouche EG; Bogdan A; Olié JP
    Psychopharmacology (Berl); 1999 Oct; 146(3):268-74. PubMed ID: 10541726
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The addition of buspirone to SSRI in the treatment of adolescent obsessive-compulsive disorder. A study of six cases.
    Thomsen PH; Mikkelsen HU
    Eur Child Adolesc Psychiatry; 1999 Jun; 8(2):143-8. PubMed ID: 10435463
    [No Abstract]   [Full Text] [Related]  

  • 24. Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder.
    Jenike MA; Baer L; Minichiello WE; Rauch SL; Buttolph ML
    Am J Psychiatry; 1997 Sep; 154(9):1261-4. PubMed ID: 9286186
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Pigott TA; Seay SM
    J Clin Psychiatry; 1999 Feb; 60(2):101-6. PubMed ID: 10084636
    [TBL] [Abstract][Full Text] [Related]  

  • 26. On the pharmacotherapy of obsessive-compulsive disorder: is a consensus possible?
    Todorov C; Freeston MH; Borgeat F
    Can J Psychiatry; 2000 Apr; 45(3):257-62. PubMed ID: 10779882
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clonazepam as an augmenting agent in the treatment of childhood-onset obsessive-compulsive disorder.
    Leonard HL; Topol D; Bukstein O; Hindmarsh D; Allen AJ; Swedo SE
    J Am Acad Child Adolesc Psychiatry; 1994; 33(6):792-4. PubMed ID: 8083135
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder.
    López-Ibor JJ; Saiz J; Cottraux J; Note I; Viñas R; Bourgeois M; Hernández M; Gómez-Pérez JC
    Eur Neuropsychopharmacol; 1996 May; 6(2):111-8. PubMed ID: 8791036
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rapid remission of OCD with tramadol hydrochloride.
    Goldsmith TB; Shapira NA; Keck PE
    Am J Psychiatry; 1999 Apr; 156(4):660-1. PubMed ID: 10200754
    [No Abstract]   [Full Text] [Related]  

  • 30. Fluoxetine in children and adolescents with OCD: a placebo-controlled trial.
    Liebowitz MR; Turner SM; Piacentini J; Beidel DC; Clarvit SR; Davies SO; Graae F; Jaffer M; Lin SH; Sallee FR; Schmidt AB; Simpson HB
    J Am Acad Child Adolesc Psychiatry; 2002 Dec; 41(12):1431-8. PubMed ID: 12447029
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sertraline-induced enuresis in a prepubertal child resolves after switching to fluoxetine.
    Maalouf FT; Gilbert AR
    J Child Adolesc Psychopharmacol; 2010 Apr; 20(2):161-2. PubMed ID: 20415614
    [No Abstract]   [Full Text] [Related]  

  • 32. Ninety-three--and washing.
    Gupta S; Austin R; Black DW
    Am J Geriatr Psychiatry; 1997; 5(4):354-5. PubMed ID: 9363293
    [No Abstract]   [Full Text] [Related]  

  • 33. Side effects as predictors of drug response in obsessive-compulsive disorder.
    Ackerman DL; Greenland S; Bystritsky A
    J Clin Psychopharmacol; 1999 Oct; 19(5):459-65. PubMed ID: 10505588
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fluoxetine: therapeutic and undesirable effects.
    Cookson J; Duffett R
    Hosp Med; 1998 Aug; 59(8):622-6. PubMed ID: 9829055
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Urinary Retention in an Adolescent Patient Caused by Fluoxetine Alone.
    Karadag M; Gokcen C; Bayar H; Aksoy I
    J Child Adolesc Psychopharmacol; 2015 Oct; 25(8):658. PubMed ID: 26485088
    [No Abstract]   [Full Text] [Related]  

  • 36. Patients with obsessive-compulsive disorder (OCD) displayed cognitive deficits consistent with a dysfunction of the dorsolateral-striatal circuit.
    Fontenelle LF; Mendlowicz MV; Versiani M
    Psychol Med; 2004 Oct; 34(7):1367-8; author reply 1368-9. PubMed ID: 15697063
    [No Abstract]   [Full Text] [Related]  

  • 37. [Compulsive-obsessive disorder after severe head trauma: diagnosis and treatment].
    Stengler-Wenzke K; Müller U; Matthes-von-Cramon G
    Psychiatr Prax; 2003 Jan; 30(1):37-9. PubMed ID: 12524581
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clomipramine-resistant, fluoxetine-responsive obsessive compulsive disorder: a case report.
    Paholpak S
    J Med Assoc Thai; 2002 Oct; 85(10):1135-8. PubMed ID: 12501907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma melatonin and cortisol circadian patterns in patients with obsessive-compulsive disorder before and after fluoxetine treatment.
    Monteleone P; Catapano F; Tortorella A; Di Martino S; Maj M
    Psychoneuroendocrinology; 1995; 20(7):763-70. PubMed ID: 8848522
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment outcome of obsessive compulsive disorder with comorbid social phobia.
    Carrasco JL; Hollander E; Schneier FR; Liebowitz MR
    J Clin Psychiatry; 1992 Nov; 53(11):387-91. PubMed ID: 1459968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.